SuperworthHeron Therapeutics profit margin HRTX
Gross, operating and net profit as a share of revenue over the last twelve months, from 2023.
- Net margin, 12 months
- −22.5%
- Operating margin, 12 months
- −7.2%
- Net margin on a year earlier
- −21.9 pts
- Peer median
- 7.6%
Over the twelve months to Jun 30, 2026, Heron Therapeutics kept −22.5% of its revenue as net profit, with an operating margin of −7.2% and a gross margin of 70.1%.
The median for 7 large drugmakers of a similar size is 7.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −13.0% | −1.6% | 73.3% |
| FY2024 | −9.4% | −8.0% | 73.2% |
| FY2023 | −87.0% | −87.1% | 48.8% |
| FY2022 | n/a | n/a | 49.0% |
| FY2021 | n/a | n/a | 46.7% |
| FY2020 | n/a | n/a | 59.2% |
| FY2019 | n/a | n/a | 57.8% |
| FY2018 | n/a | n/a | 64.5% |
| FY2017 | n/a | n/a | 85.1% |
| FY2016 | n/a | n/a | n/a |
| FY2015 | n/a | n/a | n/a |
| FY2014 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −22.5% | −21.9 pts | −7.2% | |
| Q1 FY26 | −20.5% | −15.3 pts | −6.9% | |
| Q4 FY25 | −13.0% | −3.6 pts | −1.6% | |
| Q3 FY25 | −8.8% | +11.6 pts | 1.0% | |
| Q2 FY25 | −0.6% | +34.7 pts | 0.8% | |
| Q1 FY25 | −5.2% | +56.0 pts | −2.4% | |
| Q4 FY24 | −9.4% | +77.6 pts | −8.0% | |
| Q3 FY24 | −20.3% | +77.1 pts | −18.8% | |
| Q2 FY24 | −35.3% | n/a | −34.0% | |
| Q1 FY24 | −61.3% | n/a | −62.3% | |
| Q4 FY23 | −87.0% | n/a | −87.1% | |
| Q3 FY23 | −97.4% | n/a | −98.3% |
Against its peers
Companies in Drug Manufacturers - General nearest Heron Therapeutics' size, closest first, today.
| Company | Profit margin |
|---|---|
| HRTXHeron Therapeutics | −22.5% |
| SPROSpero Therapeutics | 15.7% |
| ATNMActinium Pharmaceuticals | n/m |
| LFVNLifevantage | 2.8% |
| NATRNatures Sunshine Products | 3.7% |
| ARVNArvinas | 2.9% |
| PBYIPuma Biotechnology | 11.6% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| Peer median | 7.6% |
Where Heron Therapeutics ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Heron Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.